Search

Displaying results 4241 - 4250 of 4626 in total
  1. Drug

    AVR-RD-02

    go.drugbank.com/drugs/DB17650
    Investigational

    AVR-RD-02 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc.

  2. Drug

    Tesmilifene

    go.drugbank.com/drugs/DB04905
    Investigational

    Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast cancer.

  3. Drug

    Azficel-T

    go.drugbank.com/drugs/DB11051
    ApprovedWithdrawn

    Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. Dermal fibroblasts are collected from the post-auricular biopsy tis...

  4. Drug

    Ergometrine

    go.drugbank.com/drugs/DB01253
    ApprovedInvestigational

    An ergot alkaloid with uterine and vascular smooth muscle contractile properties.

  5. Drug

    Fostemsavir

    go.drugbank.com/drugs/DB11796
    ApprovedInvestigational

    Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-...

  6. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide. Thymosin alpha 1 is now approved in 35 developing countries for the treatment...

  7. Drug

    Selamectin

    go.drugbank.com/drugs/DB11459
    ExperimentalVet approved

    It is distributed by Zoetis, a former Pfizer subsidiary. It is structurally related to ivermectin and milbemycin. Selamectin is not approved for human use.

  8. Drug

    Siagoside

    go.drugbank.com/drugs/DB12351
    Investigational

    Treatment results in a 52% decrease in mortality 48 hours after the induction of ischemia in gerbils by permanent unilateral ligation of the common carotid artery.

  9. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    It is being developed by Exelixis, Inc.

  10. Drug

    ATG003

    go.drugbank.com/drugs/DB05069
    Investigational

    ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.